Nasus Pharma Ltd. - Asset Resilience Ratio
Nasus Pharma Ltd. (NSRX) has an Asset Resilience Ratio of 60.93% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Nasus Pharma Ltd. (NSRX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2025–2025)
This chart shows how Nasus Pharma Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NSRX total assets.
Liquid Assets Composition Over Time
This chart breaks down Nasus Pharma Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read NSRX total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.05 Million | 60.93% |
| Total Liquid Assets | $3.05 Million | 60.93% |
Asset Resilience Insights
- Very High Liquidity: Nasus Pharma Ltd. maintains exceptional liquid asset reserves at 60.93% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nasus Pharma Ltd. Industry Peers by Asset Resilience Ratio
Compare Nasus Pharma Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Chongqing Lummy Pharmaceutical
SHE:300006 |
Drug Manufacturers - General | -0.19% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Nasus Pharma Ltd. (2025–2025)
The table below shows the annual Asset Resilience Ratio data for Nasus Pharma Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.93% | $3.05 Million | $5.00 Million | -- |
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS00… Read more